MolecuLight Inc., the global leader in fluorescence imaging technology for real-time detection of harmful bacteria in wound care, is excited to announce the publication of a new study that addresses a critical challenge in wound care: the need for standardized and evidence-based antibiotic and antimicrobial prescribing. Published in Diagnostics, this groundbreaking research underscores the urgent need for widespread adoption of antimicrobial stewardship programs (ASPs) and reveals the significant potential to improve prescribing practices with MolecuLight.
The study, led by Dr. Thomas Serena and titled „Audit of Antimicrobial Prescribing Trends in 1447 Outpatient Wound Assessments: Baseline Rates and Impact of Bacterial Fluorescence Imaging“, examined antimicrobial prescribing practices in 2022 across eight U.S. outpatient wound clinics. By comparing trends between clinics with and without MolecuLight, the research provides valuable insights into current prescribing practices and the impact of MolecuLight on antimicrobial use.
https://www.mdpi.com/2075-4418/14/18/2034
